This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NGM Biopharmaceuticals (NGM) Aandelenoverzicht

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Meer informatie

NGM fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 57.57% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen zinvolle omzet ( $4M )

NGM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NGM Biopharmaceuticals, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor NGM Biopharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.54
52 Week Hoogtepunt	US$4.69
52 Week Laag	US$0.60
Bèta	1.27
1 maand verandering	1.32%
3 maanden verandering	14.93%
1 Jaar Verandering	-59.79%
3 jaar verandering	-93.94%
5 jaar verandering	-90.41%
Verandering sinds IPO	-89.52%

Recent nieuws en updates

Recent updates

Analyseartikel • Dec 19

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders are no doubt pleased to see that the share price has bounced...

Analyseartikel • Oct 05

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analyseartikel • Aug 09

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Today is shaping up negative for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...

Analyseartikel • Jun 27

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Apr 17

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

NGM Biopharmaceuticals, Inc.'s ( NASDAQ:NGM ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong...

Analyseartikel • Dec 20

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Oct 17

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

NGM Biopharmaceuticals (NASDAQ:NGM) on Monday said its phase 2 trial of its monoclonal antibody NGM621 for the treatment of eye disease geographic atrophy failed to meet its main goal. Shares of the small-cap biotech plunged 72.2% to $3.21 in premarket trading. The mid-stage trial, called CATALINA, was evaluating NGM621 for patients with geographic atrophy (GA), which is the progressive degeneration of the macula in the eye and is an advanced form of age-related macular degeneration. NGM said the trial did not meet the primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham. However, the company said the treatment showed favorable safety and tolerability. The company plans to present further analyses in early Nov. at a conference.

Seeking Alpha • Jun 30

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Siobhan Nolan Mangini, CFO of NGM Biopharmaceuticals (NASDAQ:NGM) has been appointed to the additional role of President. David J. Woodhouse, Ph.D. will continue to serve as NGM Bio’s Chief Executive Officer. William J. Rieflin, who has served as Executive Chairman of company’s Board since September 2018, will transition to Chairman of the Board effective July 1, 2022.

Seeking Alpha • Jun 21

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022. Results from a phase 1/2 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022. Results from the phase 2b ALPINE4 study using aldafermin for the treatment of patients with compensated NASH cirrhosis are expected 1st half of 2023. NGM Biopharmaceuticals had $329.8 million in cash as of March 31, 2022. It believes it has enough cash to fund its operations for at least the next 12 months.

Analyseartikel • Jun 15

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • May 09

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

Celebrations may be in order for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...

Seeking Alpha • Apr 26

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

After last year's NASH flop, NGM was written off as a lost cause. The company has been able to turn itself around. Today it is an oncology-focused company with multiple interesting assets.

Analyseartikel • Feb 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Nov 08

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Jul 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Mar 06

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Last week, you might have seen that NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) released its full-year result to the...

Rendement voor aandeelhouders

	NGM	US Pharmaceuticals	US Markt
7D	-3.1%	-1.9%	-1.8%
1Y	-59.8%	37.5%	23.3%

Rendement versus industrie: NGM presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 37.5 % opleverde.

Rendement versus markt: NGM presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 23.3 % opleverde.

Prijsvolatiliteit

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement	10.3%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van NGM is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van NGM is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	138	David Woodhouse	www.ngmbio.com

NGM Biopharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NGM Biopharmaceuticals zich tot de beurswaarde?
NGM fundamentele statistieken
Marktkapitalisatie	US$128.53m
Inkomsten(TTM)	-US$142.37m
Inkomsten(TTM)	US$4.42m

29.1x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is NGM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NGM resultatenrekening (TTM)
Inkomsten	US$4.42m
Kosten van inkomsten	US$114.23m
Brutowinst	-US$109.81m
Overige uitgaven	US$32.56m
Inkomsten	-US$142.37m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.71
Brutomarge	-2,486.12%
Nettowinstmarge	-3,223.34%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde NGM op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/04/05 10:33
Aandelenkoers aan het einde van de dag	2024/04/05 00:00
Inkomsten	2023/12/31
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

NGM Biopharmaceuticals, Inc. wordt gevolgd door 7 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Matthew Luchini	BMO Capital Markets Equity Research
Mayank Mamtani	B. Riley Securities, Inc.
Paul Choi	Goldman Sachs

This company has been acquired

NGM Biopharmaceuticals (NGM) Aandelenoverzicht

Beloningen

Risicoanalyse

NGM Biopharmaceuticals, Inc. Concurrenten

Clearside Biomedical

MediWound

Sofgen Pharma

Nektar Therapeutics

Prijsgeschiedenis en prestaties

Recent nieuws en updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

Recent updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Consensus revenue estimates fall by 26%

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Consensus revenue estimates decrease by 47%, EPS upgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Consensus EPS estimates fall by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Founder exercised options and sold US$316k worth of stock

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Price target increased to US$6.20

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting

Lead Independent Director recently bought US$462k worth of stock

Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration

Price target decreased to US$28.75

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Consensus revenue estimates fall by 11%

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021)

Price target decreased to US$32.50

NGM Biopharmaceuticals, Inc. Announces Executive Changes

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Consensus forecasts updated

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022

NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

CEO & Director exercised options to buy US$313k worth of stock.

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new directors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock